Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment.

Chikaishi Y, Uramoto H, Oka S, Nagata S, Shimokawa H, So T, Yamada S, Hanagiri T, Mukae H, Tanaka F.

Case Rep Oncol. 2014 Feb 20;7(1):126-31. doi: 10.1159/000360154. eCollection 2014 Jan.

3.

Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.

Yokoyama Y, Sonobe M, Yamada T, Sato M, Menju T, Aoyama A, Sato T, Chen F, Omasa M, Date H.

Int J Clin Oncol. 2015 Dec;20(6):1122-9. doi: 10.1007/s10147-015-0838-z. Epub 2015 May 8.

PMID:
25953679
4.
5.

Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.

Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Clin Cancer Res. 2009 Feb 1;15(3):907-13. doi: 10.1158/1078-0432.CCR-08-2251.

6.

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.

Wang YF, Xiang X, Pei X, Li S, Tang C, Wang L, Ke ZF.

Oncol Lett. 2014 Sep;8(3):1039-1042. Epub 2014 Jul 4.

7.
8.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
9.

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.

Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, Matsumura A, Iuchi K, Takada M, Kawahara M, Kawaguchi T, Yukiue H, Yokoyama T, Yano M, Fujii Y.

J Cancer Res Clin Oncol. 2008 May;134(5):569-77. Epub 2007 Oct 12.

PMID:
17932690
10.

Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).

Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T; North-East Japan Study Group.

Jpn J Clin Oncol. 2015 Jul;45(7):670-6. doi: 10.1093/jjco/hyv054. Epub 2015 Apr 15.

PMID:
25877748
11.

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.

Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Takahashi K, Yamamoto N.

Cancer Sci. 2011 May;102(5):1032-7. doi: 10.1111/j.1349-7006.2011.01887.x. Epub 2011 Feb 28.

12.

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.

Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Cancer Sci. 2010 Jan;101(1):167-72. doi: 10.1111/j.1349-7006.2009.01368.x. Epub 2009 Sep 14.

13.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
14.

Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.

Takamochi K, Suzuki K, Sugimura H, Funai K, Mori H, Bashar AH, Kazui T.

Lung Cancer. 2007 Oct;58(1):149-55. Epub 2007 Jun 4.

PMID:
17548126
15.

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S.

Cancer Res. 2008 Nov 15;68(22):9479-87. doi: 10.1158/0008-5472.CAN-08-1643.

16.

Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.

Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S.

Clin Cancer Res. 2010 Jan 1;16(1):174-83. doi: 10.1158/1078-0432.CCR-09-1204. Epub 2009 Dec 15.

17.

Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.

Yun M, Kim EO, Lee D, Kim JH, Kim J, Lee H, Lee J, Kim SH.

Cell Physiol Biochem. 2014;34(3):865-72. doi: 10.1159/000366305. Epub 2014 Aug 21.

18.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

19.

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K.

Lung Cancer. 2010 May;68(2):198-203. doi: 10.1016/j.lungcan.2009.05.022. Epub 2009 Jul 8.

PMID:
19589612
20.

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.

Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T.

Clin Cancer Res. 2010 Nov 15;16(22):5489-98. doi: 10.1158/1078-0432.CCR-10-1371. Epub 2010 Nov 9.

Supplemental Content

Support Center